Contact Us

Chemomab Completes Merger with Anchiano Therapeutics (READ MORE) (March 16, 2021)
– Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol “CMMB
– Combined company will focus on advancing Chemomab’s CM-101 currently in Phase 2 for rare fibrotic indications

Investor Relations:

Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com

Chemomab Therapeutics:

Sharon Elkobi
VP, Business Development
Phone: +972773310156
bd@chemomab.com

 

Visit Chemomab online at www.chemomab.com